Clover Health price target raised to $4.50 from $4.20 at Canaccord

Canaccord raised the firm’s price target on Clover Health (CLOV) to $4.50 from $4.20 and keeps a Buy rating on the shares. The rim said following the Q4 report they remain optimistic about the company’s opportunity going forward. For Clover, the year that was just put to bed was monumental, but more importantly Canaccord believes the outlook for additional accomplishments looks promising for several years to come.